TCBP (TC BioPharm (Holdings)) Debt-to-Equity : 0.83 (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is TC BioPharm (Holdings) Debt-to-Equity?

TC BioPharm (Holdings)'s Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.40 Mil. TC BioPharm (Holdings)'s Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $1.70 Mil. TC BioPharm (Holdings)'s Total Stockholders Equity for the quarter that ended in Jun. 2024 was $2.55 Mil. TC BioPharm (Holdings)'s debt to equity for the quarter that ended in Jun. 2024 was 0.83.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for TC BioPharm (Holdings)'s Debt-to-Equity or its related term are showing as below:

TCBP' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.36 Med: 0.75 Max: 8.39
Current: 0.83

During the past 5 years, the highest Debt-to-Equity Ratio of TC BioPharm (Holdings) was 8.39. The lowest was -1.36. And the median was 0.75.

TCBP's Debt-to-Equity is ranked worse than
83.58% of 1023 companies
in the Biotechnology industry
Industry Median: 0.14 vs TCBP: 0.83

TC BioPharm (Holdings) Debt-to-Equity Historical Data

The historical data trend for TC BioPharm (Holdings)'s Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TC BioPharm (Holdings) Debt-to-Equity Chart

TC BioPharm (Holdings) Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-1.35

-0.90

-0.59

8.40

0.67

TC BioPharm (Holdings) Quarterly Data
	Dec19	Sep20	Dec20	Jun21	Sep21	Dec21	Jun22	Dec22	Mar23	Jun23	Dec23	Mar24	Jun24
Debt-to-Equity	Get a 7-Day Free Trial								N/A	1.16	0.67	1.60	0.83

Competitive Comparison of TC BioPharm (Holdings)'s Debt-to-Equity

For the Biotechnology subindustry, TC BioPharm (Holdings)'s Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TC BioPharm (Holdings)'s Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TC BioPharm (Holdings)'s Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where TC BioPharm (Holdings)'s Debt-to-Equity falls into.

TC BioPharm (Holdings) Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

TC BioPharm (Holdings)'s Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.386	+	1.894)	/	3.399
	=	0.67

TC BioPharm (Holdings)'s Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.401	+	1.704)	/	2.55
	=	0.83

TC BioPharm (Holdings) (NAS:TCBP) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

TC BioPharm (Holdings) Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of TC BioPharm (Holdings)'s Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

TC BioPharm (Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TC BioPharm (Holdings) PLC (NAS:TCBP) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Maxim 1, 2 Parklands Way, Holytown, Motherwell, Scotland, GBR, ML1 4WR

Website

https://www.tcbiopharm.com

TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.

Executives

Renaissance Capital Partners Ltd	10 percent owner	42 SHAD THAMES, LONDON X0 SE1 2YD
Diana Elizabeth Randall	10 percent owner	C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD
Kenneth Edward Randall	10 percent owner	C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD
Mark Edward Randall	10 percent owner	C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD